Clinical Studies

The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder.

Kingsberg SA, Clayton AH, Pfaus JG.

CNS Drugs. 2015 Nov;29(11):915-33. doi: 10.1007/s40263-015-0288-1.

PMID: 26519340

Drugs in early clinical development for the treatment of female sexual dysfunction.

Belkin ZR, Krapf JM, Goldstein AT.

Expert Opin Investig Drugs. 2015 Feb;24(2):159-67. doi: 10.1517/13543784.2015.978283. Epub 2014 Nov 6. Review.

PMID: 25376023

Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies.

Ückert S, Bannowsky A, Albrecht K, Kuczyk MA.

Expert Opin Investig Drugs. 2014 Nov;23(11):1477-83. doi: 10.1517/13543784.2014.934805. Epub 2014 Aug 6. Review.

PMID: 25096243

Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.

Safarinejad MR, Hosseini SY.

J Urol. 2008 Mar;179(3):1066-71. doi: 10.1016/j.juro.2007.10.063. Epub 2008 Jan 18.

PMID: 18206919

Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study.

Safarinejad MR.

J Sex Med. 2008 Apr;5(4):887-97. doi: 10.1111/j.1743-6109.2007.00698.x. Epub 2007 Dec 28.

PMID: 18179455

Melanocortins in the treatment of male and female sexual dysfunction.

Shadiack AM, Sharma SD, Earle DC, Spana C, Hallam TJ.

Curr Top Med Chem. 2007;7(11):1137-44. Review.

PMID: 17584134

Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.

Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB.

Int J Impot Res. 2004 Apr;16(2):135-42.

PMID: 14999221